Amar U. Kishan, MD

Amar U. Kishan, MD, describes how the ArteraAI Prostate Test was built and validated, with particular attention to the RTOG 9408 data showing that more than 60% of intermediate-risk patients are biomarker-negative.

Amar U. Kishan, MD, establishes why individualized ADT decision-making remains an unsolved problem in intermediate-risk prostate cancer.

"For the MIRAGE trial specifically, we're going to continue following patients and we'll look at [data at] 5 years as well," says Amar U. Kishan, MD.

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD.

"Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided," says Amar U. Kishan, MD.

“The trial was specifically looking at whether that aggressive margin reduction from 4 mm to 2 mm would lead to a reduction in physician-reported urinary toxicity, specifically in the first 90 days after radiation,” says Amar U. Kishan, MD.

In the third article of this series, Amar U. Kishan, MD, provides clinical insights on the use of perirectal spacers for patients who receive hypofractionated radiation or SBRT.

In the third installment of this series, Amar U. Kishan, MD, discusses clinical factors to consider in the use of perirectal spacing for patients receiving hypofractionation or SBRT, and outlines unmet needs.